{"References": [{"title": "SGLT2 inhibitors and kidney protection: from mechanisms to clinical outcomes", "authors": "Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ", "journal": "Clinical Journal of the American Society of Nephrology", "year": "2018", "volumes": "13", "first page": "775", "last page": "783", "DOI": "10.2215/CJN.12391117"}, {"title": "Effects of canagliflozin on renal outcomes in type 2 diabetes and nephropathy", "authors": "Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S", "journal": "New England Journal of Medicine", "year": "2019", "volumes": "380", "first page": "2295", "last page": "2306", "DOI": "10.1056/NEJMoa1811744"}, {"title": "Dapagliflozin in patients with chronic kidney disease", "authors": "Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, McMurray JJ, Langkilde AM, Correa-Rotter R, Wheeler DC", "journal": "New England Journal of Medicine", "year": "2020", "volumes": "383", "first page": "1436", "last page": "1446", "DOI": "10.1056/NEJMoa2024816"}, {"title": "SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis", "authors": "Neuen BL, Young T, Heerspink HJ, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C", "journal": "The Lancet Diabetes & Endocrinology", "year": "2019", "volumes": "7", "first page": "845", "last page": "854", "DOI": "10.1016/S2213-8587(19)30256-6"}, {"title": "SGLT2 inhibitors in patients with type 2 diabetes and renal outcomes: a systematic review and meta-analysis", "authors": "Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL", "journal": "The Lancet", "year": "2019", "volumes": "393", "first page": "31", "last page": "39", "DOI": "10.1016/S0140-6736(18)32590-X"}, {"title": "SGLT2 inhibitors and risk of acute kidney injury: a systematic review and meta-analysis of randomized controlled trials and observational studies", "authors": "Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, Li JJ", "journal": "Diabetes, Obesity and Metabolism", "year": "2018", "volumes": "20", "first page": "910", "last page": "920", "DOI": "10.1111/dom.13170"}, {"title": "Renal outcomes with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 2 diabetes and chronic kidney disease: results from the CANVAS Program", "authors": "Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR", "journal": "The Lancet Diabetes & Endocrinology", "year": "2017", "volumes": "5", "first page": "691", "last page": "704", "DOI": "10.1016/S2213-8587(17)30123-3"}, {"title": "SGLT2 inhibitors and cardiovascular risk: an analysis of CVD-REAL", "authors": "Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M", "journal": "Journal of the American College of Cardiology", "year": "2017", "volumes": "69", "first page": "2536", "last page": "2544", "DOI": "10.1016/j.jacc.2017.03.009"}, {"title": "SGLT2 inhibitors and the risk of serious adverse events: overview of systematic reviews", "authors": "Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ", "journal": "Diabetes & Metabolism", "year": "2016", "volumes": "42", "first page": "245", "last page": "257", "DOI": "10.1016/j.diabet.2016.04.004"}, {"title": "SGLT2 inhibitors: clinical practice and future perspectives", "authors": "Scheen AJ", "journal": "Diabetes & Metabolism", "year": "2015", "volumes": "41", "first page": "S23", "last page": "S31", "DOI": "10.1016/S1262-3636(16)30005-3"}]}